Pub Date : 2026-02-01Epub Date: 2025-09-01DOI: 10.1016/j.arbres.2025.08.002
Angela Ramos-Pinedo , Jose Ignacio de Granda-Orive , Maria Isabel Cristóbal-Fernández , Calos Rábade-Castedo , Elia Pérez-Fernández , Paz Vaquero-Lozano , Maria Inmaculada Gorordo-Unzueta , Lourdes Lázaro-Asegurado , Eva de Higes-Martínez , Juan Antonio Riesco-Miranda , Rosa Mirambeaux-Villalona , Gloria Francisco-Corral , Alejandro Frino-García , Jaime Signes-Costa Miñana , Cristina Villar-Laguna , Ana Maria Cicero-Guerrero , Julio Cesar Vargas-Espinal , Teresa Peña-Miguel , Jacobo Sellares , Carlos Andrés Jiménez-Ruiz
Objectives
The main objective was to analyze the short, medium, and long-term effectiveness of a clinical–psychological care protocol for smoking cessation using cytisinicline. Other secondary objectives were evaluate safety and whether the characteristics of smoking, adherence, and the intensity of craving and withdrawal syndrome at 4th week were associated with effectiveness.
Methods
Observational, prospective, multicenter study that includes smokers motivated to quit evaluated in twelve Smoking Cessation Services in Spain.
Results
A total of 337 smokers were studied. Effectiveness of cytisinicline was 68% at the end of treatment, but was reduced to 48.7%, 40.9% and 28.2%, at 3rd, 6th and 12th month of follow up respectively. The measurement of adherence and the intensity of craving by SRC showed statistically significant association with effectiveness at 24th week, RRadj = 2.2 (p < 0.001) and RRadj = 0.87 (p = 0.011) respectively. Common adverse effects (occurring in more than 10% of patients) were: sleep disorders, headaches, dizziness and digestive disorders.
Conclusions
The effectiveness of protocol was 68% at the end of treatment, but was reduced to 48.7%, 40.9% and 28.2% at 3rd, 6th and 12th months respectively. Subjects who met more than 80% of treatment adherence doubled their chances of success at 6th month. For each point of craving intensity, measured by the SRC, at the end of the pharmacological treatment the chances of success at 6th month were reduced by 13%. Cytisinicline was safe.
{"title":"Analysis of Effectiveness of Clinical Psychological Care Protocol for Smoking Cessation With Cytisinicline","authors":"Angela Ramos-Pinedo , Jose Ignacio de Granda-Orive , Maria Isabel Cristóbal-Fernández , Calos Rábade-Castedo , Elia Pérez-Fernández , Paz Vaquero-Lozano , Maria Inmaculada Gorordo-Unzueta , Lourdes Lázaro-Asegurado , Eva de Higes-Martínez , Juan Antonio Riesco-Miranda , Rosa Mirambeaux-Villalona , Gloria Francisco-Corral , Alejandro Frino-García , Jaime Signes-Costa Miñana , Cristina Villar-Laguna , Ana Maria Cicero-Guerrero , Julio Cesar Vargas-Espinal , Teresa Peña-Miguel , Jacobo Sellares , Carlos Andrés Jiménez-Ruiz","doi":"10.1016/j.arbres.2025.08.002","DOIUrl":"10.1016/j.arbres.2025.08.002","url":null,"abstract":"<div><h3>Objectives</h3><div>The main objective was to analyze the short, medium, and long-term effectiveness of a clinical–psychological care protocol for smoking cessation using cytisinicline. Other secondary objectives were evaluate safety and whether the characteristics of smoking, adherence, and the intensity of craving and withdrawal syndrome at 4th week were associated with effectiveness.</div></div><div><h3>Methods</h3><div>Observational, prospective, multicenter study that includes smokers motivated to quit evaluated in twelve Smoking Cessation Services in Spain.</div></div><div><h3>Results</h3><div>A total of 337 smokers were studied. Effectiveness of cytisinicline was 68% at the end of treatment, but was reduced to 48.7%, 40.9% and 28.2%, at 3rd, 6th and 12th month of follow up respectively. The measurement of adherence and the intensity of craving by SRC showed statistically significant association with effectiveness at 24th week, RRadj<!--> <!-->=<!--> <!-->2.2 (<em>p</em> <!--><<!--> <!-->0.001) and RRadj<!--> <!-->=<!--> <!-->0.87 (<em>p</em> <!-->=<!--> <!-->0.011) respectively. Common adverse effects (occurring in more than 10% of patients) were: sleep disorders, headaches, dizziness and digestive disorders.</div></div><div><h3>Conclusions</h3><div>The effectiveness of protocol was 68% at the end of treatment, but was reduced to 48.7%, 40.9% and 28.2% at 3rd, 6th and 12th months respectively. Subjects who met more than 80% of treatment adherence doubled their chances of success at 6th month. For each point of craving intensity, measured by the SRC, at the end of the pharmacological treatment the chances of success at 6th month were reduced by 13%. Cytisinicline was safe.</div></div>","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"62 2","pages":"Pages 94-103"},"PeriodicalIF":9.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2025-09-12DOI: 10.1016/j.arbres.2025.09.002
Pamela J. McShane
{"title":"Are Dipeptidyl Peptidase-1 Inhibitors the Future Anti-inflammatory Treatment in Bronchiectasis?","authors":"Pamela J. McShane","doi":"10.1016/j.arbres.2025.09.002","DOIUrl":"10.1016/j.arbres.2025.09.002","url":null,"abstract":"","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"62 2","pages":"Pages 78-79"},"PeriodicalIF":9.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145430227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2025-10-04DOI: 10.1016/j.arbres.2025.09.021
João Faria Dias , Mariana Borges Dias , Gustavo Rocha
Congenital lung malformations (CLMs) encompass a range of developmental anomalies, including congenital pulmonary airway malformation (CPAM), bronchopulmonary sequestration (BPS), congenital lobar overinflation (CLO), bronchogenic cysts (BC), and bronchial atresia (BA). These lesions present with varying severity, from incidental findings to severe neonatal respiratory distress. Advances in prenatal imaging, such as ultrasound and fetal magnetic resonance image (MRI), have significantly improved early detection, aiding in better management planning.
CLMs arise from abnormalities during specific stages of lung development. CPAMs are categorized by cyst size and histological type, while BPS is characterized by systemic arterial supply. CLO and BA are associated with air trapping and hyperinflation, and BCs are typically fluid-filled, well defined, and compressive. Postnatal diagnosis is based on high-resolution computed tomography (CT) and occasionally MRI for detailed evaluation.
Surgical resection is recommended for symptomatic lesions, while management of asymptomatic cases remains debated. Elective surgery may help prevent complications like infection or rare malignancy, particularly in CPAM Types 1 and 4 and BCs. However, some lesions remain stable or regress, supporting conservative management in selected cases.
Long-term outcomes are generally positive, with children undergoing early resection often maintaining good lung function due to compensatory lung growth, though subtle functional deficits may persist. Risk stratification using imaging and genetic markers, such as DICER1 mutations, is gaining importance for guiding treatment decisions.
Management should be individualized, involving a multidisciplinary approach and shared decision-making with families. Further research is needed to clarify the natural history of CLMs, optimize the timing of interventions, and standardize long-term surveillance strategies.
{"title":"Congenital Lung Malformations: A Comprehensive Overview of Current Knowledge—Narrative Review","authors":"João Faria Dias , Mariana Borges Dias , Gustavo Rocha","doi":"10.1016/j.arbres.2025.09.021","DOIUrl":"10.1016/j.arbres.2025.09.021","url":null,"abstract":"<div><div>Congenital lung malformations (CLMs) encompass a range of developmental anomalies, including congenital pulmonary airway malformation (CPAM), bronchopulmonary sequestration (BPS), congenital lobar overinflation (CLO), bronchogenic cysts (BC), and bronchial atresia (BA). These lesions present with varying severity, from incidental findings to severe neonatal respiratory distress. Advances in prenatal imaging, such as ultrasound and fetal magnetic resonance image (MRI), have significantly improved early detection, aiding in better management planning.</div><div>CLMs arise from abnormalities during specific stages of lung development. CPAMs are categorized by cyst size and histological type, while BPS is characterized by systemic arterial supply. CLO and BA are associated with air trapping and hyperinflation, and BCs are typically fluid-filled, well defined, and compressive. Postnatal diagnosis is based on high-resolution computed tomography (CT) and occasionally MRI for detailed evaluation.</div><div>Surgical resection is recommended for symptomatic lesions, while management of asymptomatic cases remains debated. Elective surgery may help prevent complications like infection or rare malignancy, particularly in CPAM Types 1 and 4 and BCs. However, some lesions remain stable or regress, supporting conservative management in selected cases.</div><div>Long-term outcomes are generally positive, with children undergoing early resection often maintaining good lung function due to compensatory lung growth, though subtle functional deficits may persist. Risk stratification using imaging and genetic markers, such as <em>DICER1</em> mutations, is gaining importance for guiding treatment decisions.</div><div>Management should be individualized, involving a multidisciplinary approach and shared decision-making with families. Further research is needed to clarify the natural history of CLMs, optimize the timing of interventions, and standardize long-term surveillance strategies.</div></div>","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"62 2","pages":"Pages 104-112"},"PeriodicalIF":9.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145318205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2025-09-13DOI: 10.1016/j.arbres.2025.09.001
Irina González
{"title":"The Harms of Vaping: How Clinicians Can Help Patients Quit","authors":"Irina González","doi":"10.1016/j.arbres.2025.09.001","DOIUrl":"10.1016/j.arbres.2025.09.001","url":null,"abstract":"","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"62 2","pages":"Pages 75-77"},"PeriodicalIF":9.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145249486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2025-08-05DOI: 10.1016/j.arbres.2025.07.025
Antoine Léotard , Maxime Patout , Vincent Delord , Marie-Christine Blandin , Hélène Prigent , Pierre Tankéré
{"title":"Impact of CPAP in Patients With Central, Neuromuscular and Chest Wall Causes of Chronic Respiratory Failure and Comorbid OSA: A Retrospective Study","authors":"Antoine Léotard , Maxime Patout , Vincent Delord , Marie-Christine Blandin , Hélène Prigent , Pierre Tankéré","doi":"10.1016/j.arbres.2025.07.025","DOIUrl":"10.1016/j.arbres.2025.07.025","url":null,"abstract":"","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"62 2","pages":"Pages 126-129"},"PeriodicalIF":9.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144854367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2025-07-29DOI: 10.1016/j.arbres.2025.07.019
Elvan Senturk Topaloglu , Omer Topaloglu
{"title":"Spontaneous Tracheal Fistulization of a Progressive Bronchogenic Cyst: A Four-Year Conservative Follow-Up Case Report","authors":"Elvan Senturk Topaloglu , Omer Topaloglu","doi":"10.1016/j.arbres.2025.07.019","DOIUrl":"10.1016/j.arbres.2025.07.019","url":null,"abstract":"","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"62 2","pages":"Pages 139-140"},"PeriodicalIF":9.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144815742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号